• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

oncology days are numbered, force too large





My Repatha rep friend, former Oncology rep, has just got hired here at Esperion Therapeutics, Scripts at now kicking up at strong pace ever, congrats to Mary Beth, she is hitting record Nexlizet #'s, Nexletol, also Dave, Zach & large group of others among myself had biggest week. Soon dent in Ezetimibe.
 








The oncology reps make less than 2 calls a day and are critically useless. Texas empty territories are not backfilling with headcount anymore. They will merge the oncology teams and reduce headcount by 30-40% since the account managers are really the ones bringing in the business and reps are sitting there watching sales reports populate. Changes will come into effect middle of Q1 2025 as there are major patent cliffs approaching. At least you get to enjoy Christmas employed.
 
























It is confirmed that oncology will have a round of layoffs November before the holidays. They will start Q4 2024 like its business as usual. Cost cutting measures in place for obesity. Oncology products sell themselves already.